Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Adverse effects of marijuana use.

Feeney KE, Kampman KM.

Linacre Q. 2016 May;83(2):174-178.

PMID:
27833196
2.

Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues.

Regier PS, Monge ZA, Franklin TR, Wetherill RR, Teitelman A, Jagannathan K, Suh JJ, Wang Z, Young KA, Gawrysiak M, Langleben DD, Kampman KM, O'Brien CP, Childress AR.

Addict Biol. 2016 Sep 22. doi: 10.1111/adb.12445. [Epub ahead of print]

PMID:
27654662
3.

A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment.

Crist RC, Doyle GA, Kampman KM, Berrettini WH.

Drug Alcohol Depend. 2016 Sep 1;166:268-71. doi: 10.1016/j.drugalcdep.2016.07.008.

PMID:
27449273
4.

Attitudes Toward Treating Addiction With Deep Brain Stimulation.

Ali R, DiFrancesco MF, Ho AL, Kampman KM, Caplan AL, Halpern CH.

Brain Stimul. 2016 May-Jun;9(3):466-8. doi: 10.1016/j.brs.2016.03.009. No abstract available.

PMID:
27066935
5.

A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.

Kampman KM, Lynch KG, Pettinati HM, Spratt K, Wierzbicki MR, Dackis C, O'Brien CP.

Drug Alcohol Depend. 2015 Oct 1;155:105-10. doi: 10.1016/j.drugalcdep.2015.08.005.

6.

Insomnia in alcohol dependent subjects is associated with greater psychosocial problem severity.

Chaudhary NS, Kampman KM, Kranzler HR, Grandner MA, Debbarma S, Chakravorty S.

Addict Behav. 2015 Nov;50:165-72. doi: 10.1016/j.addbeh.2015.06.021.

7.

A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.

Pettinati HM, Kampman KM, Lynch KG, Dundon WD, Mahoney EM, Wierzbicki MR, O'Brien CP.

Am J Addict. 2014 Nov-Dec;23(6):591-7. doi: 10.1111/j.1521-0391.2014.12146.x.

PMID:
25251201
8.

Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.

Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, Chartier K, Kampman KM, Sharma G, Lewis DF, VanVeldhuisen P, Theobald J, May J, Brigham GS.

J Clin Psychiatry. 2014 Jul;75(7):757-64. doi: 10.4088/JCP.13m08862.

9.

The effects of quetiapine on sleep in recovering alcohol-dependent subjects: a pilot study.

Chakravorty S, Hanlon AL, Kuna ST, Ross RJ, Kampman KM, Witte LM, Perlis ML, Oslin DW.

J Clin Psychopharmacol. 2014 Jun;34(3):350-4. doi: 10.1097/JCP.0000000000000130.

PMID:
24747978
10.

Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues.

Young KA, Franklin TR, Roberts DC, Jagannathan K, Suh JJ, Wetherill RR, Wang Z, Kampman KM, O'Brien CP, Childress AR.

J Neurosci. 2014 Apr 2;34(14):5038-43. doi: 10.1523/JNEUROSCI.4977-13.2014.

11.

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM.

Am J Psychiatry. 2014 Apr;171(4):445-52. doi: 10.1176/appi.ajp.2013.13081014. Erratum in: Am J Psychiatry. 2014 May 1;171(5):585.

12.

The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction.

Clarke TK, Weiss AR, Ferarro TN, Kampman KM, Dackis CA, Pettinati HM, O'brien CP, Oslin DW, Lohoff FW, Berrettini WH.

Ann Hum Genet. 2014 Jan;78(1):33-9. doi: 10.1111/ahg.12046.

13.

Biomarkers for the development of new medications for cocaine dependence.

Bough KJ, Amur S, Lao G, Hemby SE, Tannu NS, Kampman KM, Schmitz JM, Martinez D, Merchant KM, Green C, Sharma J, Dougherty AH, Moeller FG.

Neuropsychopharmacology. 2014 Jan;39(1):202-19. doi: 10.1038/npp.2013.210. Review.

14.

Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence.

Plebani JG, Lynch KG, Rennert L, Pettinati HM, O'Brien CP, Kampman KM.

Drug Alcohol Depend. 2013 Dec 1;133(2):754-8. doi: 10.1016/j.drugalcdep.2013.06.019.

15.

A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence.

Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O'Brien CP.

Drug Alcohol Depend. 2013 Nov 1;133(1):94-9. doi: 10.1016/j.drugalcdep.2013.05.026.

16.

Case-control association study of WLS variants in opioid and cocaine addicted populations.

Crist RC, Ambrose-Lanci LM, Zeng A, Yuan C, Kampman KM, Pettinati HM, Oslin DW, O'Brien CP, Ferraro TN, Doyle GA, Lohoff FW, Berrettini WH.

Psychiatry Res. 2013 Jun 30;208(1):62-6. doi: 10.1016/j.psychres.2013.03.011.

17.

Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.

Clarke TK, Crist RC, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Ferraro TN, Lohoff FW, Berrettini WH.

Neurosci Lett. 2013 May 10;542:71-5. doi: 10.1016/j.neulet.2013.02.018.

18.

Neuronal calcium sensor-1 and cocaine addiction: a genetic association study in African-Americans and European Americans.

Multani PK, Clarke TK, Narasimhan S, Ambrose-Lanci L, Kampman KM, Pettinati HM, Oslin DW, O'Brien CP, Berrettini WH, Lohoff FW.

Neurosci Lett. 2012 Nov 30;531(1):46-51. doi: 10.1016/j.neulet.2012.09.014.

19.

Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.

Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, Ferraro TN, Hakonarson H, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Doyle GA, Lohoff FW, Berrettini WH.

Drug Alcohol Depend. 2013 Jan 1;127(1-3):122-8. doi: 10.1016/j.drugalcdep.2012.06.023.

20.

Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction.

Clarke TK, Ambrose-Lanci L, Ferraro TN, Berrettini WH, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Lohoff FW.

Genes Brain Behav. 2012 Jun;11(4):415-23. doi: 10.1111/j.1601-183X.2012.00785.x.

Items per page

Supplemental Content

Loading ...
Support Center